Asset Details
Do you wish to reserve the book?
Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma
Do you wish to request the book?
Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Carmustine (BCNU) plus Teniposide (VM26) in Recurrent Malignant Glioma
2014
Overview
Background: After the failure of radiotherapy and temozolomide, there is no established standard therapy for patients with recurrent glioblastoma (GBM). Based on the promising data of a previous trial (NOA-01) for primary GBM and some retrospective case series for GBM recurrence, the combination of nimustine and teniposide (VM26) was commonly used in this setting. When nimustine was no longer available in Europe, we switched to intrvaveneous carmustine (BCNU). Data on the toxicity and efficacy of BCNU and VM26 in recurrent GBM are lacking. Methods: In our neurooncological center, all patients with recurrent GBM or with progressed glioma and a typical MRI lesion suggesting GBM treated with BCNU (130-150 mg/m 2 , day 1/42) and VM26 (45-60 mg/m 2 , days 1-3/42) were analyzed retrospectively for progression-free survival, overall survival and toxicity. Results: Fifteen patients (median age 52 years) were identified. Median progression-free survival was 2 months and median overall survival was 4 months. Two patients (14%) developed grade 3/4 hematotoxicity. Nonhematological toxicity ≥grade 3 was not observed. Conclusion: Our data do not support the application of BCNU/VM26 in patients with late stages of recurrent GBM.
